Development of a Scalable Asymmetric Process for the Synthesis of Selective PDE4B Inhibitor Nerandomilast (BI 1015550)-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Development of a Scalable Asymmetric Process for the Synthesis of Selective PDE4B Inhibitor Nerandomilast (BI 1015550)

Published:2024-09-05 Issue: Volume: Page:
ISSN:1083-6160
Container-title:Organic Process Research & Development
language:en
Short-container-title:Org. Process Res. Dev.

Author:

Frutos Rogelio P.¹^ORCID,Tampone Thomas G.¹,Gerstmann Frank²,Weber Dirk²,Brodmann Tobias²,Hagenkötter Robert²,Abella Jocelyn³,Yang Bing-Shiou³,Mulder Jason¹^ORCID,Rodriguez Sonia¹^ORCID,Lee Heewon¹,Gao Joe³,Song Jinhua J.¹

Affiliation:

1. Department of Chemical Development, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road/P.O. Box 368, Ridgefield, Connecticut 06877-0368, United States

2. Department of Chemical Development, Boehringer Ingelheim Pharma GmbH & Co, KG, Bingerstrasse 173, Ingelheim am Rhein 55218, Germany

3. Department of Material and Analytical Sciences, Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road/P.O. Box 368, Ridgefield, Connecticut 06877-0368, United States

Publisher

American Chemical Society (ACS)

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.oprd.4c00309

Reference24 articles.

1. PDE4 inhibitors: current status

2. 1,4-Cyclohexanecarboxylates: Potent and Selective Inhibitors of Phosophodiesterase 4 for the Treatment of Asthma

3. BI 1015550 is a PDE4B Inhibitor and a Clinical Drug Candidate for the Oral Treatment of Idiopathic Pulmonary Fibrosis

4. Phosphodiesterase 4B inhibition: a potential novel strategy for treating pulmonary fibrosis

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP